June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular AMD: Interim Analysis of the CANTREAT Study
Author Affiliations & Notes
  • Peter Kertes
    Ophthalmology and Vision Sciences, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • Thomas G Sheidow
    Ivey Eye Institute, London, Ontario, Canada
  • Geoff Williams
    Calgary Retina Consultants, Calgary, Alberta, Canada
  • Mark Greve
    Alberta Retina Consultants, Edmonton, Alberta, Canada
  • Ivan Galic
    Montreal Retina Institute, Montreal, Quebec, Canada
  • Emmanouil Rampakakis
    JSS Medical Research, Saint-Laurent, Quebec, Canada
  • Joanne Gavalakis
    Novartis Pharma Canada, Dorval, Quebec, Canada
  • Andrea Scarino
    Novartis Pharma Canada, Dorval, Quebec, Canada
  • Footnotes
    Commercial Relationships   Peter Kertes, Arctic Dx (I), Bayer, Allergan, Alcon, Novartis and Genentech (F), Novartis, Alcon and Bayer (S), Novartis and Bayer (R); Thomas Sheidow, Novartis, Bayer and Alcon (S); Geoff Williams, Arctic Dx (I), Bayer, Novartis, AbbVie and Alcon (S); Mark Greve, Novartis and Alcon (S); Ivan Galic, Novartis (R); Emmanouil Rampakakis, JSS Medical Research (E); Joanne Gavalakis, Novartis (E); Andrea Scarino, Novartis (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1200. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Kertes, Thomas G Sheidow, Geoff Williams, Mark Greve, Ivan Galic, Emmanouil Rampakakis, Joanne Gavalakis, Andrea Scarino; Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular AMD: Interim Analysis of the CANTREAT Study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1200.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Age-related macular degeneration (AMD) is the leading cause of severe, irreversible vision loss in developed countries. To date, no large prospective randomized clinical studies have assessed the efficacy of a treat-and-extend (T&E) regimen compared with monthly dosing for the treatment of neovascular AMD. The purpose of this analysis was to compare the effectiveness of ranibizumab using a T&E regimen to once-monthly (OM) dosing in treatment-naïve neovascular AMD patients.

Methods : This is a 24-month, prospective, randomized (1:1), open-label, multicenter, post-authorization study. In this interim analysis, baseline characteristics, visual acuity, and injection frequency were evaluated. Summary statistics including the mean and standard deviation for continuous variables and counts and percentages for categorical variables were produced.

Results : As of November 10th, 2016, 580 patients (T&E=287; OM=293) were recruited; 404 patients (T&E=209; OM=195) and 201 patients (T&E=102; OM=99) had 12-month and 24-month follow-up, respectively. Mean (SD) age was 79.3 (7.9) years, 60.3% were females, 94.3% were Caucasian, and 22.5% had a family history of AMD. No significant between-group differences were observed. Mean (SD) baseline BCVA was 58.7 (14.2) and 59.4 (13.5) for T&E and OM, respectively, and was comparable for both groups. At Month 12, after an average of 9.2 (T&E) and 11.8 (OM) injections, mean (SD) BCVA improvement was 8.0 (12.6) and 6.2 (12.6) letters, respectively. At Month 24, after an average of 18.2 (T&E) and 23.6 (OM) injections, mean (SD) BCVA improvement was comparable between groups with 6.5 (15.3) and 6.0 (13.0) letters, respectively.

Conclusions : The results of this interim analysis show that comparable improvement in BCVA can be achieved in a real-world setting with fewer injections using a T&E compared to a monthly dosing regimen.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.